Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies how well ibrutinib and nivolumab work in treating participants
with solid tumors that have spread to other places in the body. Ibrutinib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies,
such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving
ibrutinib and nivolumab may work better in treating participants with solid tumors.